Can Mounjaro Cause Pancreatitis — and How Serious Is the Risk?

What does the MHRA actually say about tirzepatide and pancreatitis?

On 29 January 2026 the MHRA published a Drug Safety Update covering all GLP-1 receptor agonist medicines, including tirzepatide (Mounjaro). The update confirmed that acute pancreatitis is a known but infrequent adverse effect, rare enough that it does not affect most people, serious enough to warrant clear, specific guidance. The MHRA's position is that patients should be told what to watch for before they start treatment, not after something worrying happens.

That guidance is reflected in the NHS's patient information on tirzepatide, which lists severe stomach pain as a symptom requiring urgent medical attention. The Mounjaro Summary of Product Characteristics (SmPC), available on the eMC, lists pancreatitis among adverse reactions that have been reported in the trial programme and in post-marketing experience.

A question our prescribers hear most weeks is whether the risk of Mounjaro pancreatitis means the medicine isn't safe. The honest answer is that the risk is real and worth taking seriously, but it is also low in absolute terms and is not unique to tirzepatide, it has been reported across the GLP-1 class. The clinical consensus, reflected in NICE's appraisal of tirzepatide, is that the benefit-risk balance is favourable for eligible adults. Understanding the risk is part of informed decision-making, not a reason to avoid the conversation entirely.

You can read a fuller discussion of the overall pancreatitis risk with Mounjaro if you want to explore the numbers and context in more depth.

What are the warning signs that Mounjaro may have triggered pancreatitis?

Acute pancreatitis has a distinct symptom pattern that separates it from the ordinary, mild stomach upset that many people notice when they first start Mounjaro or move to a higher dose. Everyday GI symptoms (a little nausea after a meal, looser stools, some bloating) are common, usually settle within a week or two, and are not a cause for alarm. Pancreatitis is different in character, not just degree.

The hallmark is severe, persistent pain in the upper abdomen that often travels through to the back. It tends not to ease when you shift position. It may be accompanied by vomiting, and it does not resolve in the way that ordinary indigestion does. If that pattern of pain occurs at any point during treatment (at the start, mid-titration, or after you have been on a stable dose for months) stop eating and drinking and get medical help urgently. Tell the clinician you are taking tirzepatide.

People sometimes wonder about timing: does the risk concentrate around dose changes, or is it constant? The honest answer is that the data do not point to a single danger window. Some cases have been reported shortly after starting; others further into treatment. For more detail on timing patterns, our page on how soon Mounjaro can cause pancreatitis pulls together what the evidence currently shows.

Mild abdominal discomfort that responds to sitting upright or passing gas is almost certainly not pancreatitis. Severe pain that holds, intensifies, or radiates, get help the same day. If you are unsure, calling 111 before deciding is always reasonable, and for anything that feels sudden and severe, 999 or A&E without delay.

Are some people at higher risk of pancreatitis on Mounjaro?

Tirzepatide is not recommended for anyone with a history of pancreatitis, and a personal or family history of medullary thyroid carcinoma, or the hereditary condition MEN2 (Multiple Endocrine Neoplasia type 2), are also absolute contraindications. These are exactly the questions a prescriber covers during a clinical assessment, they are not background reading; they are the gate. No legitimate prescriber approves Mounjaro without checking them.

Beyond the hard contraindications, there are circumstances that raise the general pancreatitis risk in any person, regardless of which medicine they take: heavy alcohol use, gallstones, high triglyceride levels, and certain other conditions. A thorough medical history surfaces these. If any apply to you, your prescriber needs to know, it changes the benefit-risk calculation, sometimes significantly. Our page on pancreatitis caused by Mounjaro goes into more detail on how these background risk factors interact with tirzepatide specifically.

If you have already been prescribed Mounjaro elsewhere and are thinking about moving to a different provider, our prescribers review your full clinical picture and current dose as part of the process. You can read more about how Mounjaro treatment works as a whole on the Mounjaro overview page, or explore the broader side-effect profile to understand where pancreatitis sits relative to the more common GI effects.

When should you get medical help, and how do you report a suspected side effect?

Get urgent help (A&E or 999) if you develop severe, persistent upper abdominal pain that may spread to the back, especially with vomiting, and it does not ease quickly. Do not wait to see if it settles overnight. Tell the treating clinician you are taking tirzepatide and when you last took your dose.

For symptoms that are concerning but not immediately severe (persistent nausea that is worsening rather than improving after a dose change, abdominal discomfort that feels unusual for you) 111 is a sensible starting point. Your GP or the aftercare team at your prescribing service can also advise.

The MHRA runs the Yellow Card scheme so that patients can report any suspected side effect from a medicine directly. Reports from patients are genuinely useful, they contribute to ongoing safety monitoring of medicines like tirzepatide, which carries the Black Triangle (▼) symbol indicating it is subject to additional MHRA surveillance. If you experience something unexpected and are uncertain whether it is medicine-related, reporting it does not require a clinical verdict on your part. Suspicion is enough.

After any serious adverse event, it is worth notifying whoever prescribed your Mounjaro as well, so that your clinical record reflects what happened. If you have questions about how our prescribers handle safety events or ongoing monitoring, our contact page has direct routes to the aftercare team. And if you are still weighing up whether Mounjaro is right for you given this risk, starting a free consultation is the place to have that conversation properly, our prescribers discuss suitability, including side effects like this one, as part of every review.